<DOC>
	<DOCNO>NCT02168127</DOCNO>
	<brief_summary>The purpose six month , open-label study evaluate long-term safety efficacy PRC-063 adult adolescent ADHD .</brief_summary>
	<brief_title>Long-Term Safety PRC-063 Adolescents Adults With ADHD</brief_title>
	<detailed_description>This open label , multicenter , phase 3 study evaluate safety efficacy PRC-063 ( methylphenidate hydrochloride controlled-release capsule 25 , 35 , 45 , 55 , 70 , 85 100 mg/day ) treatment Attention-Deficit/Hyperactivity Disorder ( ADHD ) adolescent subject age ≥12 &lt; 18 year age adult subject age ≥18 year age . In order participate , subject must complete Purdue Pharma Study 063-009 Purdue Pharma Study 063-010 . This study conduct approximately 50 center across United States Canada . After give write informed consent ( well inform assent subject &lt; 18 year age ) , subject screen ascertain suitability study accord inclusion exclusion criterion . There seven monthly efficacy safety visit subject assess active , open-label PRC-063 . The start dose discretion Investigator . Dose-adjustment visit may occur weekly optimize subject 's dose via titration . For adolescent subject , maximum dose 85 mg/day . For adult subject , maximum dose 100 mg/day .</detailed_description>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Subjects must satisfy follow criterion enrol study adolescent : • Male nonpregnant , nonnursing female least 12 year age less 18 year age . Subjects must satisfy follow criterion enrol study adult : • Male nonpregnant , nonnursing female least 18 year age meeting local , legal definition adult . All subject must also satisfy follow criterion enrol study : Confirmation ADHD diagnosis make Visit 1 Study 063009 063010 ( inattentive , hyperactive/impulsive combinedtype , define Diagnostic Statistical Manual Mental Disorders , 5th Edition base clinician assessment use multiple informant structure interview ) . Female subject must one following : Surgically sterile prior screen Postmenopausal childbearing potential , abstinent willing use reliable method contraception , oral contraceptive , two barrier method , barrier method plus spermicidal agent . Female subject ChildBearing Potential ( FOCP ) must negative serum βhCG pregnancy test , assess Visit 6 Study 063009 063010 ( data available time entry ) . If subject adult , mentally physically competent sign inform consent document indicate understand purpose procedure require study willing participate study . If subject adolescent , mentally physically competent sign inform assent document , case subject , informed consent document , case parent/guardian , indicate understand purpose procedure require study willing participate study . Able willing comply study procedure entire length study . • Having meet exclusion criterion Study 063009 063010 . Having diagnose Study 063009 063010 stroke , epilepsy , migraine headache ( great 1 instance every two month ) , glaucoma , thyrotoxicosis , tachyarrhythmias severe angina pectoris serious unstable medical illness . Subjects control stable asthma diabetes permit . Elevated blood pressure , define value 89 diastolic 139 systolic , assessed Visit 6 Study 063009 063010 . Clinically significant ECG abnormality , assess Visit 6 Study 063009 063010 ( data available time entry ) . Clinically significant laboratory abnormality , assess Visit 6 Study 063009 063010 ( data available time entry ) . Currently receive guanethidine , pressor agent , MAO inhibitor , coumarin anticoagulant , anticonvulsant ( e.g . phenobarbital , phenytoin , primidone ) , phenylbutazone , tricyclic antidepressant ( e.g . imipramine , desipramine ) , selective serotonin reuptake inhibitor ( SSRIs ) herbal remedy ( unless stable dose 4 week ) . If Investigator judge continue treatment PRC063 subject 's best interest . Subjects currently consider suicide risk investigator . Having diagnose Study 063009 063010 schizophrenia , schizoaffective disorder , primary affective disorder , schizotypal personality , major depression , bipolar disorder , generalize anxiety , borderline personality disorder , antisocial personality another unstable psychiatric condition require treatment . Having diagnose Study 063009 063010 physiological dependence ( exclude nicotine ) narcotic analgesic psychoactive drug ( include barbiturate , opiate , cocaine , cannabinoids , amphetamine benzodiazepine ) . Excessive consumption alcohol occur Study 063009 063010 ( consumes alcohol quantity great 15 drink per week average ; 1 drink define 360 mL/12 oz . beer , 120 mL/4 oz . wine , 30 mL/1 oz . hard liquor ) . Currently ( within 30 day plan start treatment ) receive investigational drug use experimental medical device , PRC063 . Homeless .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>